Regeneron's Trading Volume Surges 64.77% to 7.12 Billion, Ranking 109th Despite Stock Price Decline

On June 20, 2025, Regeneron's trading volume reached 7.12 billion, marking a 64.77% increase from the previous day. This surge placed Regeneron at the 109th position in terms of trading volume for the day. However, the stock price of Regeneron (REGN) decreased by 0.75%.

Regeneron and Sanofi's Dupixent received FDA approval for treating bullous pemphigoid, a rare and chronic skin condition. This approval marks the eighth indication for Dupixent, expanding its therapeutic reach. The clinical trials demonstrated significant improvements in patients, providing a novel treatment option for this challenging condition.

In a phase 4 study presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, Dupixent outperformed Xolair in treating chronic rhinosinusitis with nasal polyps (CRSwNP) in patients with coexisting asthma. The study showed superior results in all primary and secondary efficacy endpoints, including nasal polyp size, sense of smell, and lung function. These findings reinforce Dupixent's efficacy in managing both upper and lower respiratory diseases by targeting key drivers of type 2 inflammation.